KMT2A and acute lymphoblastic leukemia: BH3 mimetics, and in particular venetoclax, were also highlighted as potential interventions to target specific vulnerabilities in some aggressive molecular subtypes of ALL, including hypodiploid, KMT2A-rearranged or ALL with TCF3::HLF fusion, or early T-precursor (ETP)-ALL that are associated with poor or very poor outcomes.